Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06188585 · ClinicalTrials.gov registry record · NA
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
A NA study of Acute Gastrointestinal Bleeding, sponsored by Medtronic - MITG.
- Recruiting
- Registry status
- NA
- Development phase
- 278
- Enrollment target
- 15
- Study locations
NCT06188585: Recruiting NA study of Acute Gastrointestinal Bleeding, sponsored by Medtronic - MITG.
NCT06188585 is a NA study of Acute Gastrointestinal Bleeding that is actively recruiting participants, run by Medtronic - MITG. The registered enrollment target is 278 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06188585, a NA study of Acute Gastrointestinal Bleeding, is actively recruiting participants, sponsored by Medtronic - MITG.
- RECRUITING
- Registry status
- NA
- Development phase
- 278 participants
- Enrollment target
- 15
- Study locations
Study Summary
A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due to one of the following sources: a gastric or duodenal ulcer with active bleeding (spurting or oozing) or a non-bleeding visible vessel; an esophageal, gastric or duodenal tumor with active bleeding or a non-bleeding visible vessel; a gastric or duodenal Dieulafoy lesion with active bleeding or a non-bleeding visible vessel; or an actively bleeding Mallory-Weiss tear.
Primary Outcome
Further bleeding includes patients with persistent bleeding despite study-assigned endoscopic therapy or patients with recurrent bleeding
Conditions Studied
Interventions
- DEVICE UI-EWD
- DEVICE Conventional therapy
Study Locations (15)
Other
- St. Michael's Hospital - Toronto
- Vancouver General Hospital - Vancouver
- Copenhagen University Hospital - Hvidovre
- Odense University Hospital - Odense
- St. Antoine - Paris
- Emek Medical Center - Afula
- Cleveland Clinic London - London
New York
- Northwell Health - Manhasset
- NYU Langone - New York
Alabama
- University of Alabama - Birmingham
Connecticut
- Yale - New Haven
Illinois
- RUSH University - Chicago
Massachusetts
- Brigham and Women's Hospital - Boston
New Jersey
- Rutgers University - Piscataway
Quebec
- McGill University - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06188585 shows while recruiting
NCT06188585 is an interventional study that assigns participants to a tested intervention. The registered 278 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Acute Gastrointestinal Bleeding appearing as the primary indexed condition, and to 2 interventions - of which UI-EWD is the first listed.
NCT06188585 lists 15 locations in 8 states (Other, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT06188585 about?
NCT06188585 is a clinical study titled "Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding". A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in patients presenting with acute overt gastrointestinal bleeding which is found at endoscopy to be due ...
What is the current status of trial NCT06188585?
This trial is currently recruiting. It is a NA study. The enrollment target is 278 participants. The study started on 2024-06-21. Estimated completion is 2026-08.
What conditions does trial NCT06188585 study?
This clinical trial studies the following conditions: Acute Gastrointestinal Bleeding.
What interventions are being tested in trial NCT06188585?
The interventions under investigation include: UI-EWD (DEVICE), Conventional therapy (DEVICE).
Who is sponsoring clinical trial NCT06188585?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06188585 being conducted?
This trial has 15 study locations across Alabama, Connecticut, Illinois, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06188585's enrollment target sits among peer trials
278 382nd of 2000 higher than 1,619 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04586959 · 278 participants · NA
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
- NCT05010148 · 278 participants · Phase 3
A Clinical Trial of Intravenous Lidocaine After Spinal Surgery to Prevent Delirium and Reduce Pain
- NCT05489237 · 278 participants · Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
- NCT05965245 · 278 participants · NA
Suubi-Mhealth: A Mobile Health Intervention to Address Depression Among Youth
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI